Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

Background: Patients (pts) with cancer are at higher risk for complications and mortality related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although mRNA vaccines have been granted Food and Drug Administration emergency use authorization (EUA) for prevention of COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Svoboda, Jakub, Ballard, Hatcher J, Ho, Carrie I, Hughes, Mitchell E., Chong, Elise A, Duca, Adam, Prischak, Sara, Dwivedy Nasta, Sunita, Ruella, Marco, Landsburg, Daniel J, Barta, Stefan K., Gerson, James N, Schuster, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
624.Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701684/
http://dx.doi.org/10.1182/blood-2021-153122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701684/
http://dx.doi.org/10.1182/blood-2021-153122

Ejemplares similares